Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Donna E Reece, Giovanni Piza Rodriguez, Mariela A Pantoja, Eshetu G Atenafu, Darrell White, Irwindeep Sandhu, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin Song, Jean Roy, Martha L Louzada, Arleigh McCurdy, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger E Tiedemann, Christine I Chen

Blood (2024) 144 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2024-206247

Published: 2024

Journal Articles

Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study

Donna E Reece, MD, Giovanni Piza Rodriguez, MD, Mariela A Pantoja, PhD MSc, Darrell J White, MD, Christopher P Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Martha L Louzada, MDMSc, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger E Tiedemann, MBChB, PhD, Harminder K Paul, MSc, Christine I Chen, MD

Blood (2019) 134 (Supplement_1): 4570.

https://doi.org/10.1182/blood-2019-129357

Published: 2019

Journal Articles

Targeted-Capture Sequencing Approach to V(D)J Rearrangement, Immunoglobulin (Ig) Translocation and Mutation Detection in Multiple Myeloma (MM): Potential Applications in Minimal Residual Disease (MRD) Analysis and Comparison to Multiparameter Flow Cytometry (MFC) in the Myeloma Canada Research Network (MCRN) 001 Study with Intravenous Busulfan and Melphalan (BuMel) Conditioning Followed By Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2017) 130 (Supplement 1): 3057.

https://doi.org/10.1182/blood.V130.Suppl_1.3057.3057

Published: 2017

Journal Articles

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin W. Song, MD, Jean Roy, MD, Martha L Louzada, MD, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul, BSc

Blood (2016) 128 (22): 4632.

https://doi.org/10.1182/blood.V128.22.4632.4632

Published: 2016

Journal Articles

Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Hevylite TMÂ chain (HLC) Normalization

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhDMSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Leonard Minuk, MD, Jason Tay, MD MSc, Vishal Kukreti, MD, Suzanne Trudel, MD, Prica Anca, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul

Blood (2015) 126 (23): 1982.

https://doi.org/10.1182/blood.V126.23.1982.1982

Published: 2015

Journal Articles

Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306

Reed Friend, MD, James Xenakis, Jonathan S Serody, MD, Terrance Comeau, MD, Don A. Gabriel, MD PhD, Stefanie Sarantopoulos, MD PhD, James Coghill, MD, William A. Wood, MD MPH, Andrew Sharf, Julia S Whitley, BS, Kamakshi Rao, PharmD, Christine M Walko, PharmD,BCOP, Anastasia Ivanova, PhD, Thomas C. Shea, MD, Paul M Armistead, MD PhD

Blood (2015) 126 (23): 3117.

https://doi.org/10.1182/blood.V126.23.3117.3117

Published: 2015

Journal Articles

First Report of the Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Based on Achievement of Minimal Residual Disease (MRD) Negativity

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Christopher P. Venner, MD, Darrell White, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Leonard Minuk, MD, Jason Tay, MD MSc, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD

Blood (2014) 124 (21): 3990.

https://doi.org/10.1182/blood.V124.21.3990.3990

Published: 2014

Journal Articles

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

Blood (2012) 120 (21): 813.

https://doi.org/10.1182/blood.V120.21.813.813

Published: 2012

Journal Articles

Beneficial Effect of Escalated Doses of Busulfan (BU) Delivered by Targeted Pharmacokinetics and Prolonged Continuous Infusion on Relapse Free and Overall Survival in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies

Thomas C. Shea, MD, Christine Walko, PharmD, Anastasia Ivanova, PhD, Julia Whitley, BS, Kamakshi Rao, PharmD, Don A. Gabriel, MD, PhD, Terrance Comeau, MD, FRCPC, James Coghill, MD, Paul M Armistead, MD, PhD, Stefanie Sarantopoulos, MD, PhD, William A. Wood, MD, MPH, Jonathan Serody, MD

Blood (2011) 118 (21): 1940.

https://doi.org/10.1182/blood.V118.21.1940.1940

Published: 2011

Journal Articles

Adhesion Molecule Blockade with the Humanized Anti-LFA-1 Monoclonal Antibody Efalizumab Improves Steroid Refractory Acute and Chronic Graft-Versus-Host Disease of the Skin

James M. Coghill, MD, Kristine E. Nograles, MD, James G. Krueger, MD, PhD, Amy S. Coghill, RN, MSN, Jonathan S. Serody, MD, PhD, Anastasia Ivanova, PhD, Julia Whitley, BS, Donald Gabriel, MD, PhD, Terrance Comeau, MD, Thomas Shea, MD

Blood (2008) 112 (11): 4350.

https://doi.org/10.1182/blood.V112.11.4350.4350

Published: 2008

Journal Articles

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Thomas Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Anastasia Ivanova, PhD, Dominic Moore, PhD, Robert Irons, PA, Whitley Julia, BS, Sharf Andrew, RN, Cherie Dunphy, MD, Brecher Mark, MD

Blood (2007) 110 (11): 4940.

https://doi.org/10.1182/blood.V110.11.4940.4940

Published: 2007

Journal Articles

Mitoxantrone and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplant for Multiple Myeloma.

Anne W. Beaven, MD, Terrance Comeau, MD, Andrew Sharf, RN, Dominic T. Moore, MPH, Jonathan Serody, MD, PhD, Thomas C. Shea, MD, Don A. Gabriel, MD, PhD

Blood (2006) 108 (11): 2945.

https://doi.org/10.1182/blood.V108.11.2945.2945

Published: 2006

Journal Articles

Long Term Effects on GVHD and Survival Following the Use of G-CSF Stimulated Bone Marrow Versus G-CSF Mobilized Peripheral Blood Stem Cells in HLA Matched Sibling Transplant.

Anne W. Beaven, MD, Thomas C. Shea, MD, Don A. Gabriel, MD, PhD, Terrance Comeau, MD, Robert Irons, PA, Dominic T. Moore, MS, MPH, Li Lin, MS, Andrew Sharf, RN, Carol Krasnov, Mark E. Brecher, MD, Jonathan Serody, MD, PhD

Blood (2005) 106 (11): 5385.

https://doi.org/10.1182/blood.V106.11.5385.5385

Published: 2005

Journal Articles

Clinical and Pharmacokinetic Results of a Four-Day Continuous Infusion of Full-Dose Busulfan in Patients (pts) Undergoing Matched Related (MRD) or Unrelated (MUD) Stem Cell Transplant (SCT).

Thomas C. Shea, MD, Christine Walko, PharmD, Don Gabriel, MD, PhD, Jon Serody, MD, PhD, Terrance Comeau, MD, Robert Irons, PA, Andrew Gilman, MD, Carol Krasnov, Andrew Sharf, RN, Celeste Lindley, PharmD

Blood (2005) 106 (11): 1752.

https://doi.org/10.1182/blood.V106.11.1752.1752

Published: 2005

Journal Articles

BK Viruria in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Increased Incidence in Patients Receiving Alemtuzumab (ALEM) as Conditioning Therapy and Lack of Efficacy of Cidofovir.

Terrance Comeau, MD, T. Shea, MD, D. Gabriel, MD, PhD, D. Morris, MD, R. Irons, D. Harvey, PharmD, A. Sharf, RN, C. Krasnov, C. Dunphy, MD, N. Benderenko, MD, M. Brecher, MD, J. Serody, MD, PhD

Blood (2004) 104 (11): 3160.

https://doi.org/10.1182/blood.V104.11.3160.3160

Published: 2004

Journal Articles

Successful Re-Engraftment after Second Allogeneic Transplantation for Graft Failure in Patients with Refractory Hematologic Malignancies.

Don A. Gabriel, MD, PhD, James Coghill, MD, Thomas C. Shea, MD, Terrance Comeau, MD, Robert Irons, P-AC, Carol Krasnov

Blood (2004) 104 (11): 5120.

https://doi.org/10.1182/blood.V104.11.5120.5120

Published: 2004

Journal Articles

High Relapse Rate Following Alemtuzamab Use in Allogeneic Transplants for Myeloid Hematologic Malignancies.

Thomas C. Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Donald Harvey, PharmD, Robert Irons, PA, David Morris, MD, Andrew Sharf, RN, Carol Krasnov, Cherie Dunphy, MD, Nicholas Banderenko, MD, Mark Brecher, MD

Blood (2004) 104 (11): 1826.

https://doi.org/10.1182/blood.V104.11.1826.1826

Published: 2004

NARROW

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

Beneficial Effect of Escalated Doses of Busulfan (BU) Delivered by Targeted Pharmacokinetics and Prolonged Continuous Infusion on Relapse Free and Overall Survival in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies

Adhesion Molecule Blockade with the Humanized Anti-LFA-1 Monoclonal Antibody Efalizumab Improves Steroid Refractory Acute and Chronic Graft-Versus-Host Disease of the Skin

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Mitoxantrone and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplant for Multiple Myeloma.

Long Term Effects on GVHD and Survival Following the Use of G-CSF Stimulated Bone Marrow Versus G-CSF Mobilized Peripheral Blood Stem Cells in HLA Matched Sibling Transplant.

Clinical and Pharmacokinetic Results of a Four-Day Continuous Infusion of Full-Dose Busulfan in Patients (pts) Undergoing Matched Related (MRD) or Unrelated (MUD) Stem Cell Transplant (SCT).

BK Viruria in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Increased Incidence in Patients Receiving Alemtuzumab (ALEM) as Conditioning Therapy and Lack of Efficacy of Cidofovir.

Successful Re-Engraftment after Second Allogeneic Transplantation for Graft Failure in Patients with Refractory Hematologic Malignancies.

High Relapse Rate Following Alemtuzamab Use in Allogeneic Transplants for Myeloid Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only